

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
12 September 2002 (12.09.2002)

PCT

(10) International Publication Number  
**WO 02/070018 A2**

- (51) International Patent Classification<sup>7</sup>: **A61K 47/48**
- (21) International Application Number: **PCT/GB02/00857**
- (22) International Filing Date: **1 March 2002 (01.03.2002)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:  
**0105224.0** **2 March 2001 (02.03.2001)** **GB**
- (71) Applicant (for all designated States except US): **AMERSHAM PLC** [GB/GB]; Amersham Place, Little Chalfont, Buckinghamshire HP7 9NA (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **CUTHBERTSON, Alan** [GB/NO]; Amersham Health AS, Nycoveien 2, Postboks 4220 Nydalen, N-0401 Oslo (NO). **MENDIZ-ABAL, Marivi** [ES/GB]; Amersham Health plc, The Grove Centre, White Lion Road, Amersham HP7 9LL (GB). **DIXON, Mark** [GB/GB]; Dept of Chemistry (B30), University of Southampton, Southampton SO17 3BJ (GB). **STOREY, Anthony, Eamon** [GB/GB]; Amersham Health plc, The Grove Centre, White Lion Road, Amersham, Buckinghamshire HP7 9LL (GB).
- (74) Agents: **CANNING, Lewis, Reuben et al.**; Amersham plc, The Grove Centre, White Lion Road, Amersham, Buckinghamshire HP7 9LL (GB).
- (81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.**
- (84) Designated States (regional): **ARIPO** patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), **Eurasian** patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), **European** patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), **OAPI** patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **IMPROVED PEPTIDE-CHELATE CONJUGATES**

(57) Abstract: A peptide-chelate conjugate with affinity for the ST receptor is disclosed, wherein the chelate is tetradentate. The peptide-chelate conjugate of the invention may be labelled with a radiometal to provide a metal complex. A radiopharmaceutical composition comprising the metal complex is provided, which is suitable for the diagnostic imaging of colorectal cancer. Also provided for in the invention is a kit for the preparation of the radiopharmaceutical preparation.



**WO 02/070018 A2**

**TITLE: "IMPROVED PEPTIDE-CHELATE CONJUGATES"****Field of the invention**

This invention relates to radiopharmaceuticals, in particular the invention relates to a peptide-chelate conjugate, comprising a peptide with affinity for the ST receptor. The compound of the invention is suitable for diagnostic imaging of colorectal cancer in a mammal.

The invention additionally relates to a radiolabelled peptide-chelate conjugate with affinity for the ST receptor, wherein radiolabelling of the peptide-chelate conjugate does not interfere with the affinity of the peptide for the ST receptor. In another aspect of the invention, use of such a compound for imaging of cancer of colorectal origin is provided.

A kit for the production of a radiolabelled peptide-chelate conjugate for imaging colorectal cancer is also disclosed.

**Background art**

Colorectal carcinoma (CRC) is the fourth most common malignancy worldwide following cancers of the lung, breast and prostate. Metastases of CRC origin are the main cause of death in patients diagnosed with colorectal primary tumours. Approximately 150,000 to 200,000 new cases are diagnosed annually in the USA and around 50,000 deaths are attributed to this disease. Many patients die due to the metastatic spread of the disease with 60-80% of cases developing liver lesions during the illness. The positive identification of liver metastasis is therefore a clear indication of latent disease. Although much less common, other possible sites of spread include lung, brain and occasionally bone.

Due to the strong correlation between extent of liver involvement (number and location of metastasis) and resectability, the appropriate evaluation of patients regarding suitability for surgery is becoming more important (Liver Metastasis: Biology, diagnosis and treatment. Garden O.J., Gerghty J.G., Nagorney D.M. eds. 1998). The need for an agent capable of detecting metastasis of small size (<1cm)

will have a profound impact on the treatment and management of CRC patients. There is a need to specifically detect small (<1cm) metastatic lesions in the liver. The early detection of number and location of metastatic lesions is critical. There is also a need to characterise and specifically identify the origin of the tumour with no interference from other possible lesions (e.g. cysts, benign lesions, non-treatable tumours).

A low-molecular weight heat-stable toxin is produced by enterotoxigenic strains of *E. coli*. This toxin, known as ST peptide, mediates acute diarrheal disease by binding to its receptor on colorectal cells and stimulating guanylate cyclase. Synthetic ST peptides that bind to the ST receptor without mediating acute diarrheal disease are disclosed in US 4545931 and US 4886663. These synthetically produced peptides are suitable for human administration for therapeutic and diagnostic purposes.

Targeted ligands directed towards receptors that are expressed selectively on tumour cells of colorectal origin are a means to specifically detect the presence of cancers of colorectal origin. Thus, the ST receptor is a potential target mechanism. Gastrointestinal mucosal cells specifically express the ST receptor and the expression persists after colonic and rectal mucosal cells undergo malignant neoplastic transformation. No ST peptide has been found in any other extra-intestinal tissues, therefore specificity of ligands to tissue of gastrointestinal origin is maintained. Similar levels of expression have been found in human primary and metastatic colorectal tissues with different grades of differentiation and location. A specific ligand for the ST receptor will only bind to metastatic disease, as access to the apical side of intestinal cells will be avoided if the compound is injected intravenously.

Radiolabelled ST peptides for CRC imaging and diagnosis have been previously documented. US 5518888 claims radiodiagnostic agents based on ST peptides. In one embodiment of that invention, the peptides may be linked to a radioactive imaging agent, such as radioactive iodine,  $^{111}\text{In}$  or  $^{99\text{m}}\text{Tc}$ .  $^{99\text{m}}\text{Tc}$  is chelated by DTPA, which is converted to an anhydride and reacted with an ST peptide. No other chelates are disclosed in US 5518888. Radiolabelling thus renders the peptides suitable for use in radioimaging metastasized colorectal cancers. US 6060037 discloses a method of radioimaging metastatic CRC using such radiolabelled ST peptides. The detection of localised accumulation or aggregation of radioactivity following administration of

radiolabelled ST peptide is indicative of the presence of cells with ST receptors. WO 99/21587 and WO 99/39748 also disclose radiolabelled ST peptides for diagnostic imaging. In WO 99/21587 the preferred classes of radiometal complexing agents are terpyridines and phenanthrolines. In WO 99/39748 the complexing agents comprise a  
5 macrocyclic oligo-2,6-pyridine-containing ring which is a derivative of a terpyridine, quaterpyridine, quinpyridine, or sexipyridine.

#### **Brief description of the drawings**

Figure 1 shows the effect of pH 8.0, 8.5 and 9.0 in the radiolabelling reaction on the formation of Species 2 (CA-ST<sub>5-18</sub>).

10 Figure 2 shows the effect of varying the temperature of the radiolabelling reaction on the formation of Species 2 (CA-ST<sub>5-18</sub>). The temperatures evaluated were 40°C, 60°C and 70°C.

Figure 3 shows the effect of compound mass on the percent formation of Species 2 (CA-ST<sub>5-18</sub>), tested at 12.5µg, 25µg, 50µg and 100µg compound.

15 Figure 4 shows SPECT images of mice bearing T84 tumours subcutaneously. The images are planar posterior static images with LEUHR collimator using HPLC purified <sup>99m</sup>Tc-labelled CA1-ST<sub>5-18</sub> at 20MBq per animal. Tumour to liver ratios were; 1.1 at 15 minutes, 2 at 60 minutes and 4 at 120 minutes. Image quality was comparable when crude preparations were used.

20 Figure 5 shows the relative retention of CA1-ST<sub>5-18</sub> versus the negative control, CA1-ST<sub>5-18(cys-ala)</sub>.

Figure 6 shows a comparison of HPLC purified <sup>99m</sup>Tc-labelled CA1-ST<sub>5-18</sub> and CA1-ST<sub>5-18(cys-ala)</sub> uptake in CD-1 nude mice bearing subcutaneous T84 tumours. Planar posterior static imaging with LEUHR collimator using HPLC purified CA1-ST<sub>5-18</sub> at  
25 20MBq per animal.

Figure 7 shows the biodistribution of purified CA1-ST<sub>5-18</sub> at 2MBq per animal in RNU/rnu nude rats and mice bearing T84 liver tumours. The data is expressed in as relative retention (RR) and ratios of tumour to liver and tumour to muscle.

Figure 8 shows an image of an RNU/rnu nude rat bearing T84 liver tumours. It is a planar posterior static image at 120 minutes post-injection (p.i.) using HPLC purified CA1-ST<sub>5-18</sub> at 20MBq with LEUHR collimator. The image is a whole body image with background counts removed and kidneys masked. Image tumour:liver ratio was typically 2.5.

Figure 9 shows an image of RNU/rnu nude mice bearing T84 liver tumours in the presence and absence of excess peptide. The images are planar posterior static images 120 minutes p.i. of HPLC purified CA1-ST<sub>5-18</sub> at 20MBq per animal with LEUHR collimator.

Figure 10 shows the receptor density (RD) of two human and four xenograft human cell line CRC tumours (nd = receptor density data not detected).

#### Description of the invention

ST peptides are cyclic peptides containing three disulphide bonds. It has been found that these ST peptides are unstable under the basic pH conditions required for some <sup>99m</sup>Tc chelator radiolabelling, giving in cleavage of the disulphide bridges and unacceptable loss of potency. This instability may rule out a large number of <sup>99m</sup>Tc chelates that require pH ca. 8-9 for efficient labelling. Consequently, peptide-chelate conjugates would have to be labelled under acidic conditions to maintain high potency. However, such chelates need complicated labelling protocols and can generate <sup>99m</sup>Tc-conjugates with poor efficacy, e.g., elevated hepatobiliary uptake and fast blood clearance. The present invention provides peptide-chelate conjugates that can be labelled under basic conditions without loss of potency of the ST peptide, to provide effective imaging agents.

In a first aspect, the present invention provides a peptide-chelate conjugate comprising a peptide having affinity for the ST receptor conjugated to a tetradentate chelating agent, wherein the peptide having affinity for the ST receptor comprises 10 to 25 amino acids. "A peptide having affinity for the ST receptor" is a biologically active peptide which is suitably between 10 and 25 amino acids, and preferably between 13 and 19 amino acids, derived from the ST peptide sequence, that binds the ST receptor with high affinity. The peptides of the present invention may be of

naturally occurring or synthetic origin, but are preferably synthetic. These peptides may be conjugated directly to the chelate, or by means of a "linker group". "Linker groups" may comprise a peptide sequence of about 5 to 9 amino acids, with or without the inclusion of other groups such as aliphatic chains of up to 5 carbons in length. Preferred linker groups are poly-Lys, poly-Glu, (Gly)<sub>3</sub>-(DGLu)<sub>3</sub> and (Gly)<sub>3</sub>-(aminocaproic acid)<sub>2</sub>. Labelled with a suitable radiometal, ST peptides of the invention are suitable for use as imaging agents to detect cancers of colorectal origin. Preferred peptides of the present invention are sequences 1-7.

Especially preferred peptides having affinity for the ST receptor are SEQ ID NOs 1 to 5, presented in the included sequence listing.


The negative control used in the experiments of the present invention is SEQ ID NO 8, i.e., SEQ ID NO 1 with all of the cysteines replaced with alanines and therefore lacking the disulphide bridges required for binding.

As used herein the term "tetradentate chelating agents" are chelates that are suitable for the formation of the peptide-chelate conjugates of the present invention, in which the radiometal is coordinated by the four metal donor atoms of the tetradentate chelating agent. A suitable radioactive metal ion is complexed by a tetradentate chelating agent by means of a donor set consisting of four metal donors which form at least one 5- or 6-membered chelate ring with the radiometal. Preferably, the tetradentate chelating agent forms 2 or more such 5- or 6-membered chelate rings with the radiometal. These ligands are particularly suitable for the complexation of technetium (<sup>99m</sup>Tc), but may also be used for other radiometals.

The tetradentate chelating agent is present in the conjugate in order to produce a radiolabelled form of the peptide, suitable for diagnostic imaging. A suitable radioactive metal ion may be incorporated into the peptide-chelate conjugate by means of complexation with the tetradentate chelating agent. It is an important feature of the present invention that the potency of the ST peptide is not compromised by the process of radiolabelling.

Tetradentate chelating agents suitable for the present invention include but are not limited to the following:

(i) diaminedioximes of formula A:



where  $R^{A1}$ - $R^{A6}$  are each independently an R group;


where R is H or  $C_{1-10}$  alkyl, alkylaryl, alkoxyalkyl, hydroxyalkyl, fluoroalkyl, aminoalkyl or carboxyalkyl;

and Q is a bridging group of formula  $-(W)_n-$ ;

where n is 3, 4 or 5 and each W is independently -O-, -NR- or -CR<sub>2</sub>- provided that  $(W)_n$  contains a maximum of one W group which is -O- or -NR-.

Preferred diaminedioximes have  $R^{A1}$  to  $R^{A6} = C_{1-3}$  alkyl, alkylaryl alkoxyalkyl, hydroxyalkyl, fluoroalkyl or aminoalkyl. Most preferred diaminedioximes have  $R^{A1}$  to  $R^{A6} = CH_3$ .


(ii)  $N_3S$  ligands of formula B:




where X is a thiol protecting group such as benzoyl, acetyl or ethoxyethyl that is cleaved before or during the labelling process, and;

$R^{B1}$  and  $R^{B2}$  may be H or the side chain of any amino acid.

(iii)  $N_4$  ligands of formula C:




where  $R^{C1}$ - $R^{C4}$  may be H, alkyl, aryl or combinations thereof and where one of  $R^{C1}$ - $R^{C4}$  must be a functional group such as alkylamine, alkyl sulphide, alkoxy, alkyl carboxylate, alkyl arylamine or aryl sulphide. Ligands of this type include those with C=O amide linkages. Macrocyclic versions of formula C are also included, such as:



where  $R^{C5}$  is as defined for  $R^{C1}$  to  $R^{C4}$ , above.

(iv) Diaminediphenols of formula D:



where Y is either C or N;




8

$R^{D1}$  and  $R^{D2}$  may be either H, alkyl or aryl and where one of  $R^{D1}$  and  $R^{D2}$  must be a functional group such as alkylamine, alkyl sulphide, alkoxy, alkyl carboxylate, alkyl arylamine or aryl sulphide, and;

$m = n = 1$  or  $2$ .

5 (v)  $N_2S_2$  ligands of formula E:



where Z is a thiol protecting group such as benzoyl, acetyl or ethoxyethyl that is cleaved before or during the labelling process, and;

10  $R^{E1}$ - $R^{E12}$  may be each chosen from H, an aryl group or an alkyl group and where one of  $R^{E1}$ - $R^{E12}$  must be a functional group such as alkylamine, alkyl sulphide, alkoxy, alkyl carboxylate, alkyl arylamine or aryl sulphide, and;

one or more of the pairs  $R^{E3}/R^{E4}$ ,  $R^{E5}/R^{E6}$ ,  $R^{E7}/R^{E8}$ ,  $R^{E9}/R^{E10}$  may represent a C=O bond.

15 A preferred chelating agent of the present invention is a diaminedioxime of formula A, where  $R^{A1}$ - $R^{A6}$  are all  $CH_3$ , and Q is  $-(CH_2)_2NR(CH_2)_2-$ , where R is an R group as defined for Formula (A). A most preferred chelating agent is where R of  $-(CH_2)_2NR(CH_2)_2-$  is aminoalkyl, especially  $R = -(CH_2)_2NH-$ . The latter will be referred to in the remainder of this document as "chelating agent 1" (CA1). Another preferred chelating agent is an  $N_3S$  ligand of formula B where  $R^{B1}$  and  $R^{B2}$  are both H and X is acetyl. This will be referred to as "chelating agent 2" (CA2) for the remainder of the document. "Chelating agent 3" (CA3) is an  $N_3S$  ligand of formula B where  $R^{B1}$  is  $CH_2CH_2CH_2C=O$ ,  $R^{B2}$  is H and X is ethoxyethyl.


The synthetic peptides of the present invention can be synthesised by solid phase methodology, as is well known in the art. A representative synthesis of  $ST_{5-18}$  is given

in Example 2. The peptide-chelate conjugates of the present invention can be prepared using bifunctional chelators, i.e., compounds in which the tetradentate chelator bears a pendant functional group. Preferred functional groups are amino or carboxyl functional groups, which permit facile coupling *via* amide bonds to the amine or carboxyl groups on the peptides of interest, especially the amino- or carboxyl- terminus of the peptide.

N<sub>3</sub>S bifunctional chelators can be prepared by the method of Sudhaker *et al* [Bioconjugate Chem., Vol. 9, 108-117(1998)]. The synthesis of diaminedioxime bifunctional chelators is described in Example 3. Diaminediphenol compounds can be prepared by the method of Pillai *et al* [Nucl. Med. Biol., Vol. 20, 211-216(1993)]. Bisamidedithiol compounds can be prepared by the method of Kung *et al* [Tetr. Lett., Vol 30, 4069-4072 (1989)]. Monoamidemonoaminebisthiol compounds can be prepared by the method of Hansen *et al* [Inorg. Chem., Vol 38, 5351-5358 (1999)]. Functional tetraamines can be prepared by the method of Simon *et al* [J. Am. Chem. Soc., Vol 102, 7247 (1980)]. The critical processes in the synthesis of the CA1-ST<sub>5-18</sub> conjugate can be summarised as shown in Scheme 1 on the following page.

Conjugation of the peptide to the chelate is carried out prior to the labelling reaction. The direct method of conjugation is exemplified in the compound CA1-ST<sub>5-18</sub> (or CA1-SEQ ID No 1). Conjugation *via* a linker molecule is exemplified in the compound CA1-(Gly)<sub>3</sub>-(D-Glu)<sub>3</sub>-ST<sub>5-18</sub> (or CA1-SEQ ID No 5). Conjugations may be carried out *via* either the N-terminus or the C-terminus of the peptide molecule. Refer to Table I for these structures and structures of other suitable compounds of the present invention.

The compounds of the present invention have reproducibly high radiochemical purity (RCP), advantageous pharmacokinetics such as reduced gastrointestinal uptake, and imaging efficacy in tumoured animals. The compounds offer a distinct advantage over previously disclosed CRC-targeting compounds since they have improved pharmacokinetics and specific retention in tumour tissue compared to background tissues.

**Scheme 1 Peptide assembly using automated peptide synthesiser**

In a second aspect, the present invention provides a metal complex comprising a radiometal complexed to the tetradentate chelating agent of the peptide-chelate conjugate. Preferred chelating agents for the metal complex are chosen from diaminedioximes of formula A where  $R^{A1}$ - $R^{A6}$  are all  $CH_3$  and Q is  $-(CH_2)_2NR(CH_2)_2-$ .  
5 . An especially preferred diaminedioxime of formula A is CA1, as defined above. Other preferred chelating agents for the metal complex are the  $N_3S$  ligands CA2 and CA3, defined above. A suitable radiometal may be chosen from positron emitters such as  $^{64}Cu$  and  $^{65}Cu$ , or from gamma emitters such as  $^{99m}Tc$ . A preferred embodiment of the invention is a peptide-chelate conjugate radiolabelled with  $^{99m}Tc$ .  
10 A peptide-chelate conjugate radiolabelled with  $^{99m}Tc$ , where the radiolabelling reaction is carried out at basic pH is a most preferred embodiment of the present invention.

Radiolabelling as defined by the present invention is the chemical attachment of a radiometal, such as those described above. Suitable radiolabelled compounds of the  
15 invention have affinity for the ST receptor to enable diagnostic imaging of cancers of colorectal origin. Preferred radiolabelled compounds are thus cleanly labelled with the minimum production of by-products. An example of such a by-product is reduced hydrolysed technetium (RHT) in the case of  $^{99m}Tc$  labelling. In a preferred embodiment of the invention, the peptide-chelate conjugate is labelled with  $^{99m}Tc$   
20 maintaining high RCP and low RHT levels. The results of various studies described in the Examples show that the preferred compounds of the present invention are stable to the labelling conditions and maintain their biological efficacy following radiolabelling.

The RHT levels are of particular importance in the case of  $^{99m}Tc$ -labelled conjugates  
25 of the present invention as one of the main biological targets is in the liver. RHT localises in the liver and thus if allowed to remain, will therefore increase background tissue activity, decrease target to background ratios and lead to an overall decrease in image quality. The amount of RHT is relatively low for all the preparations (Example 10). There is little difference between the labelling characteristics of CA1-ST<sub>5-18</sub> at  
30 conjugate levels of 12.5-100  $\mu g$ , in terms of the rate of formation of species 2. However, there was an increase in RHT at reduced conjugate levels (Example 10).

Compared to the non-HPLC purified unfiltered preparation, both filtering and addition of methylene diphosphonate (MDP, which is known to reduce RHT levels) had a similar effect in reducing liver uptake (Example 24). Neither method reduced background tissue counts to the level seen with HPLC purified preparations but high  
5 quality images of liver metastases are still possible with non-HPLC purified preparations.

Radiolabelling of the peptide-chelate conjugate may be carried out in a suitable buffering system such as carbonate, borate, triethanolamine hydrochloride-NaOH, dimethyleucylglycine, tris(hydroxymethyl)aminomethane, 2-amino-2-methyl-1:3-propanediol-HCl, diethanolamine-HCl, Clark and Lubs solutions (Bower and Bates, J.  
10 Res. Natn. Bur. Stand. 55, 191 (1957), Glycine, Glycylglycine or TAPS®. The labelling reaction is preferably carried out at a basic pH, i.e., between pH 8.0 and pH 10, most preferably at a pH of around 8.5. Examples 5 and 6 describe conducting the radiolabelling reaction using either sodium hydroxide or borate buffer in order to  
15 maintain a suitable pH. A preferred method of the present invention is the use of a borate buffering system in the radiolabelling reaction.

The competition binding experiments carried out (as described in Example 15) investigated the relative potency of various ST peptide compounds.  $K_i$  values in the nM range suggest good binding of competing ligand. These data show firstly that  
20 variations outside the pharmacophore in the ST peptide make little difference to binding (ST<sub>1-17</sub> vs. ST<sub>5-18</sub>,  $K_i$  0.6 and 0.4nM, respectively). The presence of CA3 on the ST peptide results in a small increase in  $K_i$ , i.e., a small resulting decrease in binding. The presence of CA1 has a greater effect on binding to reduce further the  $K_i$  value to 2.8nM, almost a ten fold reduction in binding efficacy. Binding affinity in  
25 the nanomolar range is considered acceptably high and the resulting differences in reduced binding are not observed *in vivo*. The negative control demonstrated no binding (up to 500µM).

The preferred compounds of the present invention demonstrated  $K_i$  values of less than 100nM, indicating high affinity for the receptor (see Example 17). Of all the  
30 compounds tested, CA1-ST<sub>5-18</sub>, CA3-ST<sub>5-18</sub> and CA1-gly<sub>3</sub>-Dglu<sub>3</sub>-ST<sub>5-18</sub> showed the greatest potency in this assay, with  $K_i$  values of 2.8nM, 0.8nM and 1.0nM, respectively. The *in vivo* efficacy of these screened compounds is discussed below.

The data obtained in Example 15, and the high binding ( $K_i$ ) of mock-labelled peptide (peptide subjected to the radiolabelling protocol in the absence of radiometal), supports the fact that the radiolabelled material is still bioactive.

In a third aspect, the invention also encompasses radiopharmaceutical preparations.

5 By the term "radiopharmaceutical preparation" is meant a composition comprising the radiometal complex of the invention in a form suitable for human administration. For human administration a radiopharmaceutical preparation must be sterile. It is preferably in an injectable form, e.g., for  $^{99m}\text{Tc}$ , reconstitution of the peptide-chelate conjugate with sterile pertechnetate in saline.

10 The radiopharmaceutical preparation of the present invention may also be provided in a unit dose form ready for human injection and could for example be supplied in a pre-filled sterile syringe. The syringe containing the unit dose would also be supplied within a syringe shield (to protect the operator from potential radioactive dose).

A fourth aspect of the present invention is the use of the radiopharmaceutical  
15 preparation of the invention for the imaging of cancer of colorectal origin. Imaging using the radiopharmaceutical preparation of the present invention may be carried out by means of PET or SPECT imaging, depending on the nature of the radiometal.

In a fifth aspect, the present invention provides kits for the production of the radiopharmaceutical preparation of the invention. Suitable kits are designed to give  
20 sterile radiopharmaceutical products suitable for human administration, e.g. *via* injection into the bloodstream. When the radiometal is  $^{99m}\text{Tc}$ , the kit comprises a vial containing the peptide-chelate conjugate for the metal together with a pharmaceutically acceptable reducing agent. Suitable such reducing agents are: sodium dithionite, sodium bisulphite, ascorbic acid, formamidine sulphinic acid,  
25 stannous ion,  $\text{Fe(II)}$  or  $\text{Cu(I)}$ . The pharmaceutically acceptable reducing agent is preferably a stannous salt such as stannous chloride or stannous tartrate. Alternatively, the kit may comprise a metal complex which, upon addition of the radiometal, undergoes transmetallation (i.e., ligand exchange) giving the desired product. For  $^{99m}\text{Tc}$ , the kit is preferably lyophilised and is designed to be  
30 reconstituted with sterile  $^{99m}\text{Tc}$ -pertechnetate ( $\text{TcO}_4^-$ ) from a  $^{99m}\text{Tc}$  radioisotope

generator to give a radiopharmaceutical solution suitable for human administration without further manipulation.

The peptide-chelate conjugate is preferably present in the kit in a form amenable to transport and storage over relatively long time-periods. Reconstitution with eluate  
5 from a  $^{99m}\text{Tc}$  generator under the preferred radiolabelling conditions results in a  $^{99m}\text{Tc}$ -labelled peptide with specificity for the ST receptor. It is an important feature of the present invention that in such a kit, the radiolabelling reaction does not alter the affinity of the peptide for the ST receptor.  $^{99m}\text{Tc}$ -labelled peptides of the present invention have been shown to be stable for up to 4 hrs at room temperature and in the  
10 presence of activity levels of up to 1GBq.

The above kits or pre-filled syringes may optionally contain further ingredients such as buffers; pharmaceutically acceptable solubilisers (e.g. cyclodextrins or surfactants such as Pluronic<sup>TM</sup>, Tween<sup>TM</sup> or phospholipids); pharmaceutically acceptable stabilisers, radioprotectants or antioxidants (such as ascorbic acid, gentisic acid or  
15 para-aminobenzoic acid) or bulking agents for lyophilisation (such as sodium chloride or mannitol).

It is a feature of the invention that the metal complexes have maintained potency for the ST receptor as well as suitable pharmacokinetics. Data obtained in Example 16 indicate that positive control,  $^{125}\text{I}$ -ST<sub>1-17</sub> has the highest binding of 20% of added  
20 radioactive material. The negative control, CA3-ST<sub>5-18</sub>(Cys-Ala), showed no specific binding (binding at NSB level, <1%).  $^{99m}\text{Tc}$ -labelled CA1-ST<sub>5-18</sub> shows reduced binding (6% of total added) compared to the positive control but is still significantly higher than that of the negative control. The compounds of the present invention also have optimal blood clearance, fast liver clearance and fast background tissue  
25 clearance. Liver clearance is a particularly significant feature of the present invention due to the high incidence of CRC metastases in that organ. Furthermore, the compounds of the present invention have been demonstrated to permit imaging of colorectal cancer metastases which are less than 1cm in diameter. This is a feature which additionally permits distinction to be drawn between focal and diffuse  
30 metastases. It has not been previously possible to achieve these features in an agent directed towards the ST receptor. This is therefore a surprising development over the prior art.

Metal complexes of the present invention are cleared rapidly *via* the urine (>90% at 60min p.i.). An additional feature of the present invention is low gastrointestinal uptake, which reduces the risk of unwanted side effects. Low uptake in background tissues such as liver, which may interfere with image quality, is an advantage of the metal complexes of the present invention. For CA1-ST<sub>5-18</sub> the liver uptake was 0.93% of the injected dose per gram at 2 hours p.i. (Example 17). CA1-ST<sub>5-18</sub> shows the greatest tumour to background tissue ratio, the greatest uptake (%ID/g) and relative retention of all the compounds assessed. This shows that of all the compounds examined, CA1-ST<sub>5-18</sub> showed the best pharmacokinetic qualities for a CRC imaging agent (Example 17).

The preferred mode of imaging of the present invention is SPECT imaging. It was demonstrated to be possible to image tumours of between 0.5-1 cm in diameter by SPECT imaging using the subcutaneous model (described in Example 17). The images acquired in Example 18 show that imaging is possible from 15 min p.i., and by 120 min p.i. only the tumour and kidneys are visible. The tumour size imaged was of the region expected in the target population. The images have been acquired in a planar mode, with a relatively low radioactive dose of 20 MBq/animal. Spatial resolution between organs is known to be better in humans such that the images obtained would be expected to be at least as good as seen in the animal models.

As shown in Examples 18, 19, 21 and 23, the preferred compounds of the invention display superior imaging properties not previously reported in the art. Specific *in vivo* tumour uptake has been demonstrated in two different animal models. These models are described in Examples 17 and 20. Imaging of both subcutaneous tumours and liver metastases was achieved at <2 hr p.i. in mice. It was possible to acquire images in mice from 15 minutes p.i. This will support the ideal clinical imaging window in humans of between 1-6 hours p.i.

The images produced in Example 18 (Figure 4) have consistently shown clear identification of tumours from 15 min p.i. with good ratios for tumour to muscle (not shown) and tumour to liver, which improves over time so that by 120 min p.i. only the tumour and kidneys are visible. The data obtained in Example 19 demonstrate good uptake for <sup>99m</sup>Tc-labelled CA1-ST<sub>5-18</sub> and poor uptake for the negative control (Figure 5). Planar posterior static images of the same animals acquired at 120-min p.i. show



a similar pattern; good image of  $^{99m}\text{Tc}$ -labelled CA1-ST<sub>5-18</sub> and poor image of negative control (Figure 6). In the image produced in Example 21 (figure 8), metastases are clearly visible, with a tumour:liver ratio of 1.5-3.0 based on ROI analysis. Images were acquired consistently and without major manipulation, with  
5 both of the formulations: HPLC purified and crude preparations.

Imaging experiments as described in Example 21 demonstrate specific retention of  $^{99m}\text{Tc}$ -labelled CA1-ST<sub>5-18</sub> into CRC tumours. These data support the specificity of  $^{99m}\text{Tc}$ -labelled CA1-ST<sub>5-18</sub> for ST-receptors, and highlight the importance of the conformational structure of ST peptides. When mice bearing sub-cutaneous Lewis  
10 lung tumours were injected with CA1-ST<sub>5-18</sub>, as described in Example 22, significantly higher uptake of CA1-ST<sub>5-18</sub> into colorectal tumours than into those of non-colonic origin was demonstrated.

Literature studies indicate little variation in receptor expression between tumour samples, and the reported data (80-120 fmol/mg protein) compared well with the  
15 average expression found in this study. Although a large differential in receptor expression has been seen between the two human donors (Example 25)

In biodistribution studies on a range of xenograft tumours with different ST receptor expression, highest expression was shown in T84 cells but similar to the expression in human tumours (Example 25). The relative expression in a number of different cell  
20 lines was analysed and was found to be in the following order: T84> CaCO2> LS180> HT29> SW480. The data show comparatively higher retention of CA1-ST<sub>5-18</sub> in high ST receptor-expressing tumours, CaCO2 and T84, compared to the rest. Images of tumours expressing receptor density lower than that found in human tumours (LS180) was achieved, as a result CA1-ST<sub>5-18</sub> will be able to detect a wide  
25 range of human tumours.

Expected values from previous studies suggest little loss in expression with either origin of tumour or decrease in grade. Therefore, a population of patients with low ST receptor-expressing metastases is unlikely. More importantly, the expression of receptors in human CRC tumours lies directly in between that of two imageable CRC  
30 tumours, suggesting that expression of the receptor in Human tumours is sufficient for imaging with  $^{99m}\text{Tc}$ -labelled CA1-ST<sub>5-18</sub>. Low retention in tumours was observed with



the negative control, CA3-ST<sub>5-18(cys-ala)</sub>. The data also show that despite very low receptor density there is still specific retention of <sup>99m</sup>Tc-labelled CA1-ST<sub>5-18</sub> in those tumours. The tumour uptake in tumours from T84 and LS180 cells, grown subcutaneously or in the liver of immunocompromised animals, is sufficient for  
5 imaging, as demonstrated in both the subcutaneous model and in the liver metastases model. By doing so it has been shown that it is possible to image small tumours in the region of expression levels of ST receptor found in human tumours.




The compounds of the present invention satisfy all major requirements identified for an improved CRC imaging agent, in particular successfully imaging tumours in an  
10 animal model thought to represent the more challenging aspects of the clinical disease. Exceptional efficacy has been demonstrated in the critical efficacy model of liver metastases. The preferred embodiments allow imaging of tumours that represent the range of receptor densities found in human liver metastases from CRC. The efficacy is maintained in the presence of excess peptide, at levels expected in a  
15 potential clinical formulation. Imaging studies have shown that preferred compounds are likely to be more sensitive and specific than X-ray CT. The compounds of the present invention could thus be used in the initial diagnosis of disease, and more importantly in the appropriate staging or determination of the extent of the disease, measuring response to therapy and in the follow up of patients treated for primary  
20 CRC.




The compounds of the present invention are therefore superior to any other reported CRC imaging compound. They are retained specifically in tumours of CRC origin. Imaging potential was demonstrated in a clinically acceptable time frame in a desired target tumour size. Surprising uptake, retention, pharmacokinetics, and efficacy have  
25 been demonstrated in view of reported instability of the vector at basic pH.




**Examples****Example 1 Peptide-chelate conjugates**

The compounds used are given in Table I. Conjugates were prepared as described in Example 2 as 100µg aliquots in plastic vials, and stored at -18°C. The conjugates  
5 were allowed to warm to ambient temperature before use.

**Table I: Compounds of the invention****CA3-ST<sub>5-18</sub>****CA3-ST<sub>5-18</sub> (cys-ala)**

CA1-ST<sub>5-18</sub>CA<sub>2</sub>-(Gly)<sub>2</sub>-Glu-(Lys)<sub>3</sub>-ST<sub>5-18</sub>CA<sub>2</sub>-(Gly)<sub>2</sub>-Glu-Lys-Glu-Lys-ST<sub>5-18</sub>

ST<sub>5-17</sub> C terminus amideCA2-(Phe)<sub>2</sub>-(CH<sub>2</sub>)<sub>5</sub>-ST<sub>5-18</sub>CA1-(Glu)<sub>6</sub>-ST<sub>5-18</sub>

CA1-(Lys)<sub>6</sub>-Gly-ST<sub>5-18</sub>CA1-(Gly)<sub>3</sub>-(D-Glu)<sub>3</sub>-ST<sub>5-18</sub>CA1-(Gly)<sub>3</sub>-(aminocaproic acid)<sub>2</sub>-ST<sub>5-18</sub>

**Example 2    Synthesis of CA1-ST<sub>5-18</sub>****2.1 Solid-phase synthesis**

The solid-phase assembly of the peptide sequence was performed on the support Fmoc-Tyr(tBu)-SASRIN (10 g polymer; 0.6 mmol/g loading) using an Advanced  
5 Chemtech 90 automated peptide synthesiser. The amino acids were all of the L-configuration with the  $\alpha$ -amino function blocked with the 9-Fluorenylmethoxycarbonyl (Fmoc) protecting group.

The reactive side-chain functional groups were bearing the following protecting groups:

- 10            Trityl (Trt) - for cysteines 6 and 14 and asparagine,  
  
              Acetamidomethyl (Acm)- for cysteines 5 and 10,  
  
              4-Methoxybenzyl (Mob) – for cysteines 9 and 17,  
  
              tert-Butyl ester – for glutamic acid  
  
              tert-Butyl ether – for tyrosine

15    **2.2 Coupling and deprotection reactions**

Double coupling cycles were carried out using a 5-fold excess of activated Fmoc-amino acid derivatives dissolved in N-methylpyrrolidone (NMP). The first coupling was carried out with Fmoc amino acid/DIC/HOBt activation, and the second coupling with Fmoc amino acid/HBTU/HOBt/DIEA activation.

- 20    Excess reagents were removed from the polymer by washing three times with NMP, three times with methanol and three times with NMP before removal of the Fmoc group in 20% piperidine/NMP (5 minute and 20 minute cycles performed). Once assembled the peptide resin was washed three times with NMP, three times with DCM and three times with methanol before drying overnight in a vacuum oven at  
25    room temperature. Weight of final resin 20.76 g (yield 84.2%).

### 2.3 Cleavage of partially protected peptide from the solid support

To the dry peptide resin in the nitrogen bubbler was added TFA (25 ml) containing 5% TIS and 5% water and the mixture bubbled under nitrogen for 30 minutes. The peptide solution was then drained into toluene (200 ml) and evaporated *in vacuo* at  
5 RT. Cold diethyl ether was added to the oily residue in order to precipitate out the product as a solid. Following trituration with diethyl ether and drying, 600 mg of the crude dithiol peptide was obtained. The HPLC purity of the crude product was shown to be around 70% with several side-products identified due to modifications during the TFA cleavage step. The most significant impurity (10-15%) was caused by the  
10 cleavage of one of the CA1 oxime side arms.

### 2.4 Cyclisation 1: oxidation of the crude dithiol peptide: 6,14 disulphide

Crude dithiol peptide from 2.3 above (0.132 mmol, 300 mg) was dissolved portionwise in 600 mL of 0.1M  $\text{NH}_4\text{HCO}_3$  (pH 8) in water/acetonitrile (80:20) containing potassium ferricyanate (0.3 mmol, 100 mg). The reaction was left stirring  
15 under nitrogen for 16 hours then HPLC analysis was used to confirm complete conversion of starting dithiol to oxidised product. The peptide solution was then acidified to pH 2 with TFA, filtered through a 0.45 micron filter (Millipore) then pumped directly onto the preparative HPLC column and gradient elution initiated. Fractions of >80% purity were combined and freeze-dried yielding 140 mg of the  
20 desired product.

### 2.5 Cyclisation 2: Acm group deprotection and cyclisation 6,14; 5,10

The mono-disulphide product from 2.4 above (0.14 g, 0.062 mmol) was dissolved in 150 ml of acetic acid/DMSO (1:1) containing 0.1 mL anisole and iodine (0.1 g, 0.39 mmol) added. The reaction mixture was stirred in the dark for 30 minutes before  
25 dilution to a total volume of 450 ml with distilled water. The peptide solution was then extracted twice with diethyl ether in a separating funnel and the aqueous phase analysed by HPLC.

HPLC analysis revealed the presence of two new products present in a 4:1 ratio. Both products had the desired molecular weight as evidenced by MS analysis and  
30 corresponded to two conformational isomers. The aqueous layer was once again filtered through a 0.45 micron filter (Millipore) before pumping directly onto the



preparative HPLC column and gradient elution initiated. Fractions of >80% purity were combined and freeze-dried yielding 40 mg of the desired product.

### 2.6 Cyclisation 3: Mob group deprotection and cyclisation

To the bis-disulphide product from 2.5 above (40 mg, 0.019 mmol) was added a solution of 10% DMSO/TFA (50 ml) containing 0.1 ml of anisole and the mixture gently shaken (20 min.). The TFA was evaporated *in vacuo* at room temperature and the product precipitated by the addition of diethyl ether. Following trituration with diethyl ether 25 mg of the fully folded product was recovered. Preparative HPLC of crude product and freeze-drying yielded 16 mg of the desired product (purity >98%). MS analysis by LCQ; found (M+H)<sup>+</sup> = 1873, expected (M+H)<sup>+</sup> = 1873.

### 2.7: Salt exchange

The pure TFA salt from above was dissolved in water containing 0.1 % ammonium acetate. Gradient elution on a C18 reverse phase column using a 10 to 60 %B gradient over 40 minutes where buffer A= 0.1 % ammonium acetate/ H<sub>2</sub>O; B= 0.1 % ammonium acetate in 80% acetonitrile/H<sub>2</sub>O) was performed. The acetate salt (15 mg) was recovered following freeze-drying.

### **Example 3    Synthesis of chelating agent 1 (CA1)**

To a solution of *tris*-(2-aminoethyl) amine (Aldrich; 2 ml, 13 mmol) in acetonitrile (20 ml) was added sodium bicarbonate (2.2 g, 26 mmol). A solution of 3-chloro-3-methyl-2-nitrosobutane (1.8 g, 13 mmol) in dry acetonitrile (10 ml) was added slowly at 0°C. The reaction mixture was left to stir at room temperature for 4 hours, and then filtered. The filtrant was washed with acetonitrile and the filtrate evaporated. The crude product was dissolved in acetonitrile and purified by HPLC (Hamilton PRP-1; A: 2% aqueous NH<sub>3</sub>, B: MeCN; 0-100%B in 20 min; 3 ml/ min) to afford CA1. Yield: 0.88g, 19%.

### **Example 4    Conjugation of peptide to chelating agent**

#### 4.1 Coupling of succinic acid linker

An aliquot (1 g, ca 0.3 mmol) of the peptide resin from Example 2 was transferred to a nitrogen bubbler where a further set of washes in DMF (3 X 15 ml) were carried

out. A solution containing 1 mmol of succinic anhydride dissolved in DMF (20 ml) was then added and the mixture bubbled under nitrogen for 30 minutes. The polymer was washed with 5 X 15 ml quantities of DMF and a resin sample taken for analysis by Kaiser Test to confirm the absence of free amino groups.

5    4.2 Coupling of chelating agent 1 (CA1)

The resin bound acid functionality was then pre-activated *in situ* by the addition of a solution in DMF (15 ml) containing PyAOP (0.52 g, 1 mmol), HOAt (0.14 g, 1 mmol) and NMM (0.2 ml, 2 mmol). On-resin activation was carried out for 10 minutes followed by addition of a solution in DMF (10 ml) of CA1 (0.4 g, 1.1 mmol). The  
10    mixture was bubbled for 3 hours then excess reagents removed by filtration followed by washing with DMF (5 X 15 ml), DCM (3 X 15 ml) and ether (3 X 15 ml). The peptide-resin was then dried in a stream of nitrogen.

**Example 5    Radiolabelling: sodium hydroxide method**

An aliquot of conjugate (100µg) was dissolved in nitrogen-purged saline (900µl) and  
15    added to a silanised P6 vial using silanised pipette tips. The pH of the solution was adjusted to pH 8.5 with 0.01M sodium hydroxide solution and the vial capped. To the solution was added Na<sup>99m</sup>TcO<sub>4</sub> (1ml, 1GBq/ml) from a freshly eluted generator (eluate less than 2 hours old). The pH of the solution was again adjusted to pH 8.5 with 0.01M sodium hydroxide solution. Freshly prepared nitrogen-purged SnCl<sub>2</sub>  
20    solution (0.1ml, 10mg/100ml saline) was then added to the solution. The pH of the solution was again adjusted to pH 8.5 with 0.01M sodium hydroxide solution. The vial was shaken after each addition to ensure mixing. The preparation was left to stand at room temperature.

**Example 6    Radiolabelling: borate buffer method**

25    12.5 mM borate buffer (1ml) was added to an aliquot of conjugate and sonicated for 30 seconds. The resulting solution was added to a silanised P6 vial, using silanised pipette tips, and the vial capped. To the solution was added Na<sup>99m</sup>TcO<sub>4</sub> (1 ml, 1 GBq/ml) from a freshly eluted generator (eluate less than 2 hours old). Freshly prepared nitrogen-purged SnCl<sub>2</sub> solution (0.1ml, 10 mg/100 ml saline) was then added  
30    to the solution. The vial was shaken after each addition to ensure mixing.

**Example 7    Labelling analysis**

Investigation of the labelling characteristics of the CA1 conjugates was performed by labelling CA1-ST<sub>5-18</sub> using the sodium hydroxide method outlined in Example 5. Simultaneous HPLC and ITLC analysis was performed at approximately 15, 60 and  
5    120 minutes post reconstitution. In addition, preparative HPLC was performed to obtain pure samples of the two <sup>99m</sup>Tc species. ITLC analysis was performed on each purified sample to confirm agreement between the two analytical techniques. Further studies were performed on alternative CA1 conjugates to confirm the observed labelling characteristics.

10    The results of the initial investigation of the labelling characteristics showed a single major <sup>99m</sup>Tc species at early time points, converting almost completely to a second species over a number of hours. Good agreement between ITLC and HPLC analysis was observed. Two <sup>99m</sup>Tc-conjugate species were resolved by both HPLC and ITLC and the relative quantities of each species correlated well. For further confirmation,  
15    preparative HPLC was performed to obtain pure samples of the two species.

**Example 8    Effect of pH on radiolabelling**

The effect of pH on the labelling characteristics was investigated by comparing the labelling of CA1-ST<sub>5-18</sub> (100µg), using the borate buffer method outlined in Example 6, at pH 8.1, 8.5 and 9.0. ITLC analysis was performed at 15, 30, 60, 90, 120 and 180  
20    minutes post-reconstitution. A relatively narrow pH range was studied due to the known instability of the ST<sub>5-18</sub> vector to high pH, caused by the presence of three disulphide bridges.

The results of the comparison of the labelling of CA1-ST<sub>5-18</sub> at pH 8.1, 8.5 and 9.0 are shown (Figure 1). The results are expressed as % species 2 formed, as seen by ITLC  
25    (Gelman ITLC/SG paper, 70:30 saline: acetonitrile eluent) analysis.

**Example 9    Effect of temperature on radiolabelling**

The effect of temperature on the labelling characteristics was investigated by comparing the labelling of CA1-ST<sub>5-18</sub> (100 µg), using the borate buffer (pH 9.0) method outlined above, followed by heating at 40, 60 and 75°C. Each preparation

was allowed to stand at room temperature for 10 minutes post reconstitution then heated for 20 minutes. ITLC analysis was performed prior to heating (10 minutes post reconstitution), 10 minutes post heating (40 minutes post reconstitution) and 60 minutes post heating (100 minutes post reconstitution).

- 5 The results of the comparison of the labelling of CA1-ST<sub>5-18</sub> at 40, 60 and 70°C are shown (Figure 2). The results are again expressed as % Peak 2 formed, as measured by ITLC (Gelman ITLC/SG paper, 70:30 saline: acetonitrile eluent) analysis.

***Example 10 Effect of conjugate level on radiolabelling***

- 10 The effect of conjugate level on the labelling characteristics was investigated by comparing the labelling of various amounts of CA1-ST<sub>5-18</sub> (12.5, 25, 50 and 100µg) using the borate buffer (pH 9.0) method outlined above. ITLC analysis was performed at 15, 30, 60, 90, 120 and 180 minutes post reconstitution.

The results of the labelling CA1-ST<sub>5-18</sub> at varying levels (12.5, 25, 50 and 100 µg, equivalent to  $6.6 \times 10^{-9}$ ,  $1.3 \times 10^{-8}$ ,  $2.7 \times 10^{-8}$  and  $5.3 \times 10^{-8}$  moles) are shown (Figure 3).

- 15 The results are expressed as the percentage of species 2 formed, as seen by ITLC (Gelman ITLC/SG paper, 70:30 saline: acetonitrile eluent) analysis. RHT data has been shown (Table II).

**Table II: RHT levels in radiolabelled preparations.**

	100µg	50µg	25µg	12.5µg
RHT (%)	0.6	1.5	1.9	2.7

**Example 11 Stability of conjugate to labelling conditions**

To establish the stability of the starting material to the labelling conditions, an inactive, "blank" labelling experiment was performed. A "blank" labelling involved the substitution of saline for Na<sup>99m</sup>TcO<sub>4</sub>. CA1-ST<sub>5-18</sub> (100µg) was subjected to the borate buffer labelling method (pH 9.0, 60°C, 20 minutes). The starting material was then HPLC purified and a competition binding assay performed to determine whether there was any loss of affinity for the receptor compared with before the labelling procedure. HPLC analysis was performed to detect any degradation of the compound.

No degradation of the compound was observed by HPLC and potency (measured by competition binding assay) did not significantly alter.

**Example 12 Competition between CA1-benzamide and ST<sub>5-18</sub>**

To investigate co-ordination of <sup>99m</sup>Tc to the peptide conjugate, a competition study was performed. Firstly, CA1-benzamide (which was chosen to mimic the CA1 portion of CA1-ST<sub>5-18</sub>) and ST<sub>5-18</sub> were labelled independently using the borate buffer method (pH9.0, 60°C for 20 minutes) and characterised by HPLC and ITLC. For the competition study, equimolar quantities of CA1-benzamide (31µg, 6.92x10<sup>-8</sup>) and ST<sub>5-18</sub> (100µg, 6.92x10<sup>-8</sup>) were labelled together in the same pot using the borate buffer method. ITLC and HPLC analyses, as outlined in Examples 13 and 14, determined where the technetium had co-ordinated.

**Example 13 ITLC**

Gelman ITLC/SG paper eluted with saline

Gelman ITLC/SG paper eluted with methylethyl ketone (MEK, 2-butanone)

Gelman ITLC/SG paper eluted with a 70:30 v/v mixture of saline and acetonitrile

Whatman No. 1 (W1) paper eluted with a 50:50 v/v mixture of water and acetonitrile

**Example 14 HPLC**

All analysis was carried out using Gilson hardware and Unipoint software.

Column: Phenomenex Luna C-18, 4.6 x 250mm, 5  $\mu$ m

Eluent A: 0.1% acetic acid (pH raised to pH 5.0 with ammonia) in 90% water/10%  
5 acetonitrile

Eluent B: 0.1% acetic acid (pH raised to pH 5.0 with ammonia) in 10% water/90%  
acetonitrile

Flow: 1ml/min

UV Detector:  $\lambda$ =230nm

10 Similar gradients were used for the different conjugates. A typical gradient was:

T<sub>0</sub>: 0% B

T<sub>5</sub>: 15% B

T<sub>20</sub>: 15% B

T<sub>21</sub>: 0% B

15 T<sub>30</sub>: 0% B

**Example 15 Competition binding assay**

Compounds were assessed for their potency by radioligand binding assay to determine inhibition constant (K<sub>i</sub>) as a measure of potency of binding. Methods are described elsewhere, but briefly, [<sup>125</sup>I]ST<sub>1-17</sub> was competed with cold ST compounds (0.0001 –  
20 50  $\mu$ M) in 96 well plates containing ca. 1  $\mu$ g rat intestinal membrane and incubated 1 hr, 37°C. Samples were filtered (GF/B filters, Whatman) to retrieve bound radiolabelled peptide and counted to determine % Bound/Free.

Potency of compounds was determined by inhibition constant (K<sub>i</sub>) for their ability to compete with radioligand, [<sup>125</sup>I]ST<sub>1-17</sub>. Potencies of screened compounds are shown  
25 in Table III.

**Table III: K<sub>i</sub> assay data for CRC compounds. K<sub>i</sub> values shown are means of triplicate values of assay wells. Non-specific binding accounts for less than 0.1% in all cases and total binding (no competing peptide) is no greater than 20%.**

Compound	Mean Ki value (nM)	Comments
ST <sub>1-17</sub>	0.6	ST peptide
ST <sub>5-18</sub>	0.4	Selected Core Vector
CA3-ST <sub>5-18</sub>	0.8	Labelled
CA3-ST <sub>5-18</sub> (cyc-ala)	none	Negative Control
CA1-ST <sub>5-18</sub>	2.8	Unlabelled
CA-ST <sub>5-18</sub>	3.5	Mock-labelled

**Example 16 Radioactive binding assay**

To determine whether radiolabelling affected the binding of the compound, labelled compounds were tested for their ability to bind the receptor. Briefly HPLC purified radiolabelled compounds (ca. 0.05 nM) were incubated with 6 µg/150 µl final volume of rat intestinal membrane (one hour), in the presence and absence of competing peptide (50 µM ST<sub>5-18</sub>). Samples were filtered (GF/B filters, Whatman) to retrieve bound radiolabelled peptide and counted to determine % Bound/Free. Non-specific binding accounted for less than 1% in all cases.

In order to ensure that potency was maintained post-labelling, an assay measuring binding of labelled compounds was developed.

**Example 17 Biodistribution in a subcutaneous tumour model**

The sub-cutaneous model was used as an appropriate initial *in vivo* screen. Briefly, mice (female nude CD-1, ca. 20 g; Charles River) were injected sub-cutaneously into the neck with T84 human colon carcinoma cells (0.1 ml, 1x10<sup>8</sup> cells/ml in medium) through a 23-gauge needle and allowed to develop tumours over 6-8 weeks.

At least three animals per test point were studied. Results are expressed as % injected dose per gram (%ID/g) of tissue. Due to the fast clearance of <sup>99m</sup>Tc-labelled CA1-ST<sub>5-18</sub> (greater than 90% excreted *via* urine 60mins p.i.) tumour uptake is also expressed as relative retention (RR).

Compounds were screened for their uptake into sub-cutaneous T84 tumours in the mouse (Table IV). This model allows assessment of the imageability of CA1-ST<sub>5-18</sub> by allowing comparison between tumour and background tissue uptake.

**Table IV: Screening data for compounds of the invention.**

Screen	CA3-ST <sub>5-18</sub> 18(cys-ala)	CA3-ST <sub>5-18</sub> 18	CA1-ST <sub>5-18</sub> 18	CA1-lys <sub>6</sub> - gly-ST <sub>5-18</sub>	CA1-gly <sub>3</sub> - Dglu <sub>3</sub> -ST <sub>5-18</sub>
Ki value (nM)	none	0.8	2.8	72	1
HBS (% id at 2 hours p.i.)	26	5	1.0	1.48	0.71
Urinary (%id at 2 hours p.i.)	32	90	>90	76	63
Liver (%id at 2 hours p.i.)	0.93	0.5	0.1	4.9	0.46
Tumour uptake & ratios					
% id/g at 2 hours p.i.)	0.21	0.8	0.94	1.0	0.26
RC at 2 hours p.i.	0.1	0.24	0.32	0.3	0.08
RR at 2 hours p.i.	0.17	2.5	6.4	1.6	1.9
Tumour/liver	0.08	2	12.4	0.23	0.63
Retention over 2 hours	8	30	20	34	5.5

**5 Example 18 Imaging in the subcutaneous tumour model**

Tumours were grown as in Example 17. Animals were monitored for tumour growth for 8 to 10 weeks, until tumours were 0.5 – 1 cm in size. After this time, animals were injected with test article (0.1 ml, 20 MBq/ml or 200 MBq/ml) as an intravenous bolus *via* the tail vein. At various times p.i. animals were euthanased and whole body planar images acquired between 5 minutes and 24 hours p.i. using a gamma camera (Park Medical Isocam-1). Image acquisition times were typically 15-30 min or 150-250K counts (whole body, LEUHR collimator).

**Example 19 Uptake of <sup>99m</sup>Tc-labelled CA1-ST<sub>5-18</sub> and CA3-ST<sub>5-18</sub>(cys-ala) (negative control) into CRC tumours**

CA3-ST<sub>5-18</sub>(cys-ala) has the same peptide sequence as <sup>99m</sup>Tc-labelled CA1-ST<sub>5-18</sub>, except all cysteines have been replaced by alanine amino acids, removing the three disulphide bridges required for binding. CA3-ST<sub>5-18</sub>(cys-ala) also contains the CA3 as opposed to CA1 and so was labelled using a suitable protocol for this chelate. To examine the uptake and retention of CA3-ST<sub>5-18</sub> (cys-ala) and <sup>99m</sup>Tc-labelled CA1-ST<sub>5-18</sub>, CD-1 nude mice bearing sub-cutaneous T84 tumours were injected, euthanased and dissected at various times p.i. The data is presented in figures 5 and 6.



**Example 20 Biodistribution in liver metastases model**

The liver metastases model was used in both mice and rats. As for the subcutaneous tumour model except in establishing tumours, cells were injected *via* the spleen and allowed to transfer to the liver *via* the circulation. Two minutes after injection of  
5 cells, a splenectomy was performed. Animals were allowed to generate tumours over 6-8 weeks.

Animals were monitored for tumour growth for 8 to 10 weeks, until tumours were 0.5 – 1 cm in size. After this time, animals were injected with test article (0.1 ml, 20 MBq/ml or 200 MBq/ml) as an intravenous bolus *via* the tail vein. At various times  
10 p.i. animals were euthanased. Muscle, kidneys, urine, lung, liver, stomach, small intestine, large intestine, thyroid and tumour were dissected and a blood sample taken. Dissected tissues, blood samples and standards were weighed and counted (Wallac Wizard). At least three animals per test point were studied. Results are expressed as %ID/g of tissue. Due to the fast clearance of <sup>99m</sup>Tc-labelled CA1-ST<sub>5-18</sub> (greater than  
15 90% excreted *via* urine 60 mins p.i.) tumour uptake is also expressed as RR (Figure 7).

**Example 21 Imaging in liver metastases model**

Tumours were grown in animal as described in Example 20. Animals were monitored for tumour growth for 8 to 10 weeks, until tumours were 0.5 – 1 cm in size. After this  
20 time, animals were injected with test article (0.1 ml, 200 MBq/ml) as an intravenous bolus *via* the tail vein. At various times p.i. animals were euthanased and whole body planar images acquired between 5 minutes and 24 hours p.i. using a gamma camera (Park Medical Isocam-1). Image acquisition times were typically 15-30 min or 150-250K counts (whole body, LEUHR collimator). The uptake of <sup>99m</sup>Tc-labelled CA1-  
25 ST<sub>5-18</sub> in the rat liver metastases model is shown (Figure 8). The image has the kidneys masked to improve the resolution of the imaged metastases.

**Example 22 Uptake of CA1-ST<sub>5-18</sub> into a non colonic tumour**

To examine the specificity of the compounds of the present invention for colonic carcinomas, C57BL/6 mice bearing sub-cutaneous Lewis lung tumours were injected  
30 with CA1-ST<sub>5-18</sub> and dissected at various times p.i. Lewis lung is carcinoma that

originally spontaneously arose in the lung of C57BL/6 mice and therefore is not of colorectal origin and is not thought to express the ST receptor.

***Example 23 ST receptor mediated Uptake of CAT-ST<sub>5-18</sub>***

To further examine the specificity of the compounds of the present invention for  
5 colonic carcinomas, nude mice bearing T84 tumours as described in Example 17 were imaged. Co-injection of 100µg/mouse of ST peptide injected with CA1-ST<sub>5-18</sub> reduced the uptake by 40%. (Figure 9).

***Example 24 Effect of impurities***

It was observed that there was an increase in background tissue activity observed with  
10 non-HPLC purified preparations; this could be potentially due to several factors: presence of excess peptide, presence of <sup>99m</sup>Tc labelled impurities (e.g. RHT or others). Further studies were carried out to investigate the other possible causes for the increased background seen with non-HPLC purified preparations, different approaches to reduce impurities such as RHT were tested. Preparations were either  
15 filtered (0.2 µm filter size) or had MDP added, known to reduce RHT levels.


***Example 25 Comparison of tumour model used with Human tissue***

T84 receptor density data show good comparison with those of human liver metastases (Figure 10). Direct comparison of human liver metastases and xenograft  
tumour receptor density (Bmax) data clearly show that mean receptor density of  
20 human tumours lies in between that seen for T84 and LS180 tumours.

In order to determine whether uptake varied with differences in receptor density, biodistribution studies were undertaken in a range of xenograft tumours with different ST receptor expressions.


# Claims

- 1) A peptide-chelate conjugate comprising a peptide having affinity for the ST receptor conjugated to a tetradentate chelating agent, wherein the peptide having affinity for the ST receptor comprises 10 to 25 amino acids.
- 2) The peptide-chelate conjugate of claim 1 wherein the peptide having affinity for the ST receptor comprises 13 to 19 amino acids.
- 3) The peptide-chelate conjugate of claim 1 or 2 where the tetradentate chelating agent is chosen from diaminedioximes,  $N_3S$  ligands,  $N_4$  ligands, diaminediphenols and  $N_2S_2$  ligands.
- 4) The peptide-chelate conjugate of claims 1 to 3 where the tetradentate chelating agent is chosen from diaminedioximes and  $N_3S$  ligands.
- 5) The peptide-chelate conjugate of claims 1 to 4 where the tetradentate chelating agent is one that forms a complex with  $^{99m}Tc$  at basic pH.
- 6) The peptide-chelate conjugate of claims 1 to 5 where the tetradentate chelating agent is of formula A:



where  $R^1$ - $R^6$  are all  $CH_3$  and Q is  $-(CH_2)_2NR(CH_2)_2-$ .

- 7) The peptide-chelate conjugate of claims 1 to 5 where the tetradentate chelating agent is of formula B:



where  $R^1$  and  $R^2$  are both H and X is a thiol protecting group.

- 8) The peptide-chelate conjugate of claims 1 to 7 where the peptide is chosen from SEQ ID Nos. 1 to 7.
- 5 9) The peptide-chelate conjugate of claims 1 to 8 where the conjugation is either at the N-terminus or at the C-terminus of the peptide.
- 10) The peptide-chelate conjugate of claims 1 to 9 which further comprises a linker group between the peptide and the tetradentate chelating agent.
- 11) The peptide-chelate conjugate of claim 10 where the linker group comprises a peptide sequence of 5 to 9 amino acids.
- 10 12) The peptide-chelate conjugate of claims 10 and 11 where the linker group is selected from -poly-Lys-, -poly-Glu-, -(Gly)<sub>2</sub>-Glu-(Lys)<sub>3</sub>-, (Gly)<sub>2</sub>-Glu-Lys-Glu-Lys-, (Phe)<sub>2</sub>-(CH<sub>2</sub>)<sub>5</sub>-, (Lys)<sub>6</sub>-Gly-, -(Gly)<sub>3</sub>-(DGLu)<sub>3</sub>- and -(Gly)<sub>3</sub>-(aminocaproic acid)<sub>2</sub>-.
- 15 13) A metal complex which comprises a radiometal complexed to the tetradentate chelating agent of the peptide-chelate conjugate of claims 1 to 12.
- 14) The metal complex of claim 13 where the radiometal is chosen from <sup>64</sup>Cu, <sup>65</sup>Cu and <sup>99m</sup>Tc.
- 15) The metal complex of claims 13 and 14 where the radiometal is <sup>99m</sup>Tc.
- 20 16) A radiopharmaceutical composition in a form suitable for human administration, which comprises the metal complex of claims 13 to 15.
- 17) The radiopharmaceutical composition of claim 16, where the radiometal is <sup>99m</sup>Tc.

18) Use of the radiopharmaceutical composition of claims 16 and 17 for imaging cancer of colorectal origin.

19) A kit for the preparation of the radiopharmaceutical composition of claims 16 and 17 which comprises:

- 5    i)            the peptide-chelate conjugate of claims 1 to 12
- ii)          a reducing agent

20) The kit of claim 19 where the reducing agent is a stannous salt.

21) The kit of claims 19 and 20 further comprising one or more of stabilisers; antioxidants; bulking agents for lyophilisation; and solubilisers.


Figure 1


Figure 2


Figure 3




Figure 4


Figure 5

Figure 6





Figure 7

Figure 8




Figure 9





Figure 10



## SEQUENCE LISTING

<110> Amersham plc  
 <120> Improved Peptide-chelate Conjugates  
 <130> PZ0107  
 <160> 8  
 <170> PatentIn version 3.1  
 <210> 1  
 <211> 14  
 <212> PRT  
 <213> Artificial Sequence  
 <220>  
 <223> Synthetic Peptide  
 <400> 1  
 Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Ala Gly Cys Tyr  
 1 5 10  
 <210> 2  
 <211> 17  
 <212> PRT  
 <213> Artificial Sequence  
 <220>  
 <223> Synthetic Peptide  
 <400> 2  
 Asn Ser Ser Asn Tyr Cys Glu Leu Cys Cys Asn Pro Ala Cys Ala Gly  
 1 5 10 15  
 Cys  
 <210> 3  
 <211> 21  
 <212> PRT  
 <213> Artificial Sequence  
 <220>  
 <223> Synthetic peptide  
 <400> 3  
 Glu Glu Glu Glu Glu Glu Gly Cys Cys Glu Leu Cys Cys Asn Pro Ala  
 1 5 10 15  
 Cys Ala Gly Cys Tyr  
 20  
 <210> 4  
 <211> 21  
 <212> PRT  
 <213> Artificial sequence  
 <220>  
 <223> Synthetic peptide



&lt;400&gt; 4

Lys Lys Lys Lys Lys Lys Gly Cys Cys Glu Leu Cys Cys Asn Pro Ala  
1 5 10 15

Cys Ala Gly Cys Tyr  
20

<210> 5  
<211> 20  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Synthetic peptide

<220>  
<221> D amino acid  
<222> (4)..(6)  
<223>

<220>  
<221> D amino acid  
<222> (4)..(6)  
<223>

&lt;400&gt; 5

Gly Gly Gly Glu Glu Glu Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys  
1 5 10 15

Ala Gly Cys Tyr  
20

<210> 6  
<211> 19  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Synthetic peptide

<220>  
<221> MISC\_FEATURE  
<222> (4)..(5)  
<223> X indicates aminocaproic acid

&lt;400&gt; 6

Gly Gly Gly Xaa Xaa Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Ala  
1 5 10 15

Gly Cys Tyr

<210> 7  
<211> 17  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Synthetic peptide

<220>  
<221> MISC\_FEATURE  
<222> (3)..(3)  
<223> X indicates (CH<sub>2</sub>)<sub>5</sub>

<400> 7

Phe Phe Xaa Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Ala Gly Cys  
1 5 10 15

Tyr

<210> 8  
<211> 14  
<212> PRT  
<213> Atrificial sequence

<400> 8

Ala Ala Glu Leu Ala Ala Asn Pro Ala Ala Ala Gly Ala Tyr  
1 5 10

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
12 September 2002 (12.09.2002)

PCT

(10) International Publication Number  
**WO 02/070018 A3**

- (51) International Patent Classification<sup>7</sup>: **A61K 47/48**, G01N 33/60
- (21) International Application Number: PCT/GB02/00857
- (22) International Filing Date: 1 March 2002 (01.03.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
0105224.0 2 March 2001 (02.03.2001) GB
- (71) Applicant (*for all designated States except US*): **AMERSHAM PLC** [GB/GB]; Amersham Place, Little Chalfont, Buckinghamshire HP7 9NA (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **CUTHBERTSON, Alan** [GB/NO]; Amersham Health AS, Nycoveien 2, Postboks 4220 Nydalen, N-0401 Oslo (NO). **MENDIZ-ABAL, Marivi** [ES/GB]; Amersham Health plc, The Grove Centre, White Lion Road, Amersham HP7 9LL (GB). **DIXON, Mark** [GB/GB]; Dept of Chemistry (B30), University of Southampton, Southampton SO17 3BJ (GB). **STOREY, Anthony, Eamon** [GB/GB]; Amersham Health plc, The Grove Centre, White Lion Road, Amersham, Buckinghamshire HP7 9LL (GB).
- (74) Agents: **CANNING, Lewis, Reuben** et al.; Amersham plc, The Grove Centre, White Lion Road, Amersham, Buckinghamshire HP7 9LL (GB).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— with international search report
- (88) Date of publication of the international search report:  
5 December 2002
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: TETRADENTATE PEPTIDE-CHELATE CONJUGATES FOR COLORECTAL CANCER DIAGNOSIS

(57) Abstract: A peptide-chelate conjugate with affinity for the ST receptor is disclosed, wherein the chelate is tetradentate. A low-molecular weight heat-stable toxin is produced by enterotoxigenic strains of E. Coli. This toxin, known as ST peptide, mediates acute diarrheal disease by binding to its receptor on colorectal cells and stimulating guanylate cyclase. Gastrointestinal mucosal cells specifically express the ST receptor and the expression persists after colonic and rectal mucosal cells undergo malignant neoplastic transformation. The peptide-chelate conjugate of the invention may be labelled with a radiometal to provide a metal complex. In a preferred embodiment, the radiometal is <sup>99m</sup>Tc, and the chelating agent is selected from: diaminedioxime, diaminediphenol, N3S, N4 and N2S2 Ligands. A radiopharmaceutical composition comprising the metal complex is provided, which is suitable for the diagnostic imaging of colorectal cancer. Also provided for in the invention is a kit for the preparation of the radiopharmaceutical preparation.

WO 02/070018 A3

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 02/00857

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K47/48 G01N33/60

According to International Patent Classification (IPC) or to both national classification and IPC,

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 95 11694 A (UNIV JEFFERSON ; WALDMAN SCOTT A (US)) 4 May 1995 (1995-05-04) * page 41, lines 5-8 and 28-30; page 42, lines 4-10; page 55, lines 1-5; page 59 lines 13-24; paragraph joining pages 59 and 60; page 99, lines 7-10; examples 12 and 13 *	1-5, 8-21
Y	US 6 007 792 A (CIVITELLO EDGAR R ET AL) 28 December 1999 (1999-12-28) * paragraph joining columns 2 and 3; formulae V-XII on columns 11-14; column 20, lines 29-34; claims 1, 12 *	1-5, 8-21
	-/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*G\* document member of the same patent family

Date of the actual completion of the international search

28 August 2002

Date of mailing of the international search report

05/09/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Fausti, S

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 02/00857

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	KWAMENA E BAIDOO ET AL: "SYNTHESIS OF A DIAMINEDITHIOL BIFUNCTIONAL CHELATING AGENT FOR INCORPORATION OF TECHNETIUM-99M INTO BIOMOLECULES" BIOCONJUGATE CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 1, no. 2, 1990, pages 132-137, XP000371813 ISSN: 1043-1802 * page 132, left-hand column, lines 29-31; page 134, paragraph joining left- and right-hand columns; page 135, left-hand column, lines 16-25; page 136, left-hand column, lines 13-15; chart I * ---	1-3,5, 8-21
Y	WO 95 00553 A (LISTER JAMES JOHN ;DIATECH INC (US); DEAN RICHARD T (US); MCBRIDE) 5 January 1995 (1995-01-05) * page 5, lines 2-10; page 31, line 6; page 35, lines 7-13; table 1, line 2; example 2 * ---	1-3,5, 8-21
Y	WO 97 10852 A (DINKELBORG LUDGER ;ERBER SEBASTIAN (DE); KRAMP WOLFGANG (DE); RADU) 27 March 1997 (1997-03-27) * page 5, line 35; page 6, lines 1-36; paragraph joining pages 13 and 14; examples 2,6 * -----	1-3,5, 8-21

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

Continuation of Box I.1

Although claim 18 is directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition of claim 16 or 17.

-----  
Continuation of Box I.1

Claims Nos.: 18

Rule 39.1(iv) PCT - Diagnostic method practised on the human or animal body

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/GB 02/00857

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 18  
because they relate to subject matter not required to be searched by this Authority, namely:  
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 02/00857

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9511694	A	04-05-1995	US 5518888 A	21-05-1996
			US 5601990 A	11-02-1997
			AU 681920 B2	11-09-1997
			AU 8124994 A	22-05-1995
			CA 2174928 A1	04-05-1995
			EP 0734264 A1	02-10-1996
			JP 9506340 T	24-06-1997
			NO 961706 A	20-06-1996
			WO 9511694 A1	04-05-1995
			US 6268159 B1	31-07-2001
			US 6087109 A	11-07-2000
			US 5962220 A	05-10-1999
			US 5879656 A	09-03-1999
			US 6060037 A	09-05-2000
			US 5928873 A	27-07-1999
			US 5731159 A	24-03-1998
US 6007792	A	28-12-1999	US 5849261 A	15-12-1998
			AU 710923 B2	30-09-1999
			AU 5529696 A	16-10-1996
			BR 9607933 A	02-06-1998
			CA 2216851 A1	03-10-1996
			CN 1186443 A , B	01-07-1998
			EP 0820313 A2	28-01-1998
			HU 9801390 A2	28-10-1998
			IL 117725 A	28-01-2001
			JP 11503420 T	26-03-1999
			NO 974494 A	21-11-1997
			NZ 306677 A	29-11-1999
			PL 322589 A1	02-02-1998
			RU 2171117 C2	27-07-2001
			TW 449482 B	11-08-2001
			WO 9630055 A2	03-10-1996
			ZA 9602527 A	21-01-1997
WO 9500553	A	05-01-1995	US 6017509 A	25-01-2000
			AT 199089 T	15-02-2001
			AU 701083 B2	21-01-1999
			AU 7099094 A	17-01-1995
			CA 2167281 A1	05-01-1995
			DE 69426673 D1	15-03-2001
			DE 69426673 T2	20-09-2001
			DK 720621 T3	06-08-2001
			EP 1092726 A2	18-04-2001
			EP 1099707 A2	16-05-2001
			EP 0720621 A1	10-07-1996
			ES 2158897 T3	16-09-2001
			SG 48977 A1	18-05-1998
			WO 9500553 A1	05-01-1995
			US 5997844 A	07-12-1999
			US 6214316 B1	10-04-2001
			US 6183722 B1	06-02-2001
			US 6074627 A	13-06-2000
			US 6017512 A	25-01-2000
			AT 203754 T	15-08-2001
			AU 690071 B2	23-04-1998
			AU 4768893 A	24-01-1994
			DE 69330521 D1	06-09-2001



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 02/00857

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9500553	A	DE 69330521 T2	16-05-2002
		DK 649434 T3	12-11-2001
		EP 0649434 A1	26-04-1995
		JP 8503924 T	30-04-1996
		US 5871711 A	16-02-1999
		ZA 9404498 A	24-06-1996
WO 9710852	A	DE 19536781 A1	27-03-1997
	27-03-1997	AU 1435997 A	09-04-1997
		CA 2232391 A1	27-03-1997
		WO 9710852 A2	27-03-1997
		EP 0853488 A2	22-07-1998